Biliary

<!-- Name:DistributionId Value:8840969 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

Selbyville, Delaware, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The biliary stents market value is anticipated to surpass USD 699 million by 2032, as per a new research report announced by Global Market Insights Inc. Number of people being…

Newark, New Castle, USA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- As per the report published by Growth Plus Reports the Global Biliary Stents Market was estimated at US$ 358.26 million in 2021 and is expected to surpass a valuation of US$…

Elana Gotkine MONDAY, Jan. 23, 2023 (HealthDay News) -- For patients with biliary tract cancer (BTC), no significant improvement is observed in overall survival with the addition of albumin-bound…

New York, USA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Primary Biliary Cirrhosis Clinical Trial Pipeline Insights Featuring 22+ Companies | DelveInsight Primary biliary cholangitis, previously called primary biliary cirrhosis, is a chronic…

Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the second- and third- line settings; at least…

Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the…

CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies Compass Plans to Initiate Stage 2 of…

NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic…

Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data Readouts and Dosing of First Patients in…